Articles tagged with: ASH 2012 Meeting

News»

[ by and | Jan 22, 2013 2:35 pm | 20 Comments ]
Trends In The Use Of Stem Cell Transplantation For Multiple Myeloma (ASH 2012)

Findings from a retrospective study of stem cell transplantation among U.S. and Canadian multiple myeloma patients show that the technique has become more common in the past 15 years.

In addition, the outcomes associated with the procedure have improved over time.

“There was progressively improved survival for multiple myeloma patients managed with autologous stem cell transplantation as an initial therapy,” said Dr. Luciano Costa from the Medical University of South Carolina, who presented the results at the American Society for Hematology (ASH) annual meeting last month.

“Stem cell transplants have …

Read the full story »

News»

[ by | Updated: Jan 16, 2013 3:35 pm | 4 Comments ]
Different M-Spike After Stem Cell Transplantation Linked To Improved Survival (ASH 2012)

Results of a Canadian retrospective analysis indicate that multiple myeloma patients who develop one or more new monoclonal proteins (M-spikes) after stem cell transplantation may have improved progression-free and overall survival compared to those without a new M-spike.

Myeloma cells overproduce a single type of antibody, known as a monoclonal or M-protein. Different types of myeloma are classified according to the type of M-protein the patient’s myeloma cells produce.

When a patient’s original M-spike disappears and an M-spike of a different monoclonal protein appears, this is known as monoclonal banding.  …

Read the full story »

News»

[ by | Jan 11, 2013 1:31 pm | 19 Comments ]
Risk Of Infection Among Multiple Myeloma Patients Is High And Rising (ASH 2012)

Results from a recent retrospective study demonstrate that the risk of infection is significantly higher in multiple myeloma patients compared to the general population.

Furthermore, the study investigators found that the rate of infection in myeloma patients has increased in recent years.

“Our study raises the question whether modern myeloma therapy increases the risk of infections,” said Dr. Cecilie Blimark from the Sahlgrenska University Hospital in Gothenburg, Sweden, who presented the study findings at the American Society of Hematology (ASH) annual meeting last month.

“The increasing risk [of developing an …

Read the full story »

News»

[ by and | Jan 9, 2013 12:37 pm | One Comment ]
Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)

Daratumumab continues to show promise for relapsed and refractory multiple myeloma patients. Results from a Phase 1/2 study indicate that daratumumab may be effective and safe in heavily pretreated patients.

In particular, daratumumab’s activity as an anti-myeloma agent seems at least as good as that of the newest myeloma therapies.

“The response to daratumumab was accompanied by the clearance of myeloma cells,” said Dr. Torben Plesner from the Vejle Hospital in Denmark, who presented the findings from the daratumumab trial at the 2012 American Society of Hematology (ASH) meeting last …

Read the full story »

News»

[ by | Jan 4, 2013 3:54 pm | Comments Off ]
Lorvotuzumab Mertansine Combination Effective In Relapsed/Refractory Multiple Myeloma Patients (ASH 2012)

Results from an ongoing Phase 1 study demonstrate that lorvotuzumab mertansine in combination with Revlimid and dexamethasone is effective as a therapy for relapsed and refractory myeloma patients.

The updated trial results were presented by Dr. Jesus Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, the American Society of Hematology (ASH) annual meeting in Atlanta last month.

Ten patients are currently continuing with the clinical trial. According to Dr. Berdeja, these interim results support the continued evaluation of the combination in relapsed and refractory myeloma patients. “This was …

Read the full story »